ID

38421

Description

Study ID: 103414 Clinical Study ID: 103414 Study Title: A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal surgery Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00038961 https://clinicaltrials.gov/ct2/show/NCT00038961 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Fondaparinux Sodium Trade Name: Fondaparinux Sodium Study Indication: Thrombosis This phase III placebo-controlled trial studies the efficacy and safety of Fondaparinux as an additional prevention measure of venous thromboembolic events (VTE) in patients above the age of 40 with intermediate or high VTE risk undergoing abdominal surgery. The study consists of a Screening Visit (Visit 0), the baseline visit on Day 1, the day of the surgery (Visit 1), the treatment period (denoted in its entirety as Visit 2) consisting of administration of Fondaparinux (2.5mg subcutaneously once daily) or placebo starting on Day 1 and continuing at least up to Day 5, possibly up to Day 9, in parallel to intermittent pneumatic compression and possibly elastic stockings, followed by a mandatory bilateral venography no longer than 24 hours after study drug cessation, and finally a Follow-up Visit (Visit 3) on Day 30 +/- 2. This form contains information on prior, concomitant and follow-up medication, and is to be filled in repeatedly starting one week prior to study start up to the end of the follow-up period.

Lien

https://clinicaltrials.gov/ct2/show/NCT00038961

Mots-clés

Versions (1)
  1. 17/10/2019 17/10/2019 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

17 octobre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Fondaparinux in Addition to Intermittent Pneumatic Compression in Abdominal Surgery Patients at VTE Risk - NCT00038961

Anglais

Medication Record

1 Formulaires  
  1. StudyEvent: ODM
    1. Medication Record
Administrative data
Description

Administrative data

Alias
UMLS CUI-1
C1320722
Country No.
Description

Country No.

Type de données

integer

Alias
UMLS CUI [1,1]
C0454664
UMLS CUI [1,2]
C0600091
Centre No.
Description

Centre No.

Type de données

integer

Alias
UMLS CUI [1,1]
C1301943
UMLS CUI [1,2]
C0600091
Subject No.
Description

Clinical Trial Subject Unique Identifier

Type de données

integer

Alias
UMLS CUI [1]
C2348585
Subject Initials
Description

Subject Initials

Type de données

text

Alias
UMLS CUI [1,1]
C1997894
UMLS CUI [1,2]
C2986440
None
Description

If no concomitant medication, skip the rest of the form.

Type de données

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0549184
Concomitant Medication Record
Description

Concomitant Medication Record

Alias
UMLS CUI-1
C2347852
Drug Name
Description

Drug Name

Type de données

text

Alias
UMLS CUI [1]
C0013227
Total Daily Dose/Units
Description

Concomitant Agent Total Daily Dose

Type de données

text

Alias
UMLS CUI [1]
C2826638
Route
Description

Concomitant Medication Route

Type de données

text

Alias
UMLS CUI [1]
C2826730
Prior
Description

Prior Medication- Recording is limited to treatment with anti-platelet agents, anticoagulant agents, fibrinolytics starting within 1 week prior to first dose.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332185
UMLS CUI [1,2]
C2826667
UMLS CUI [1,3]
C2963157
UMLS CUI [2,1]
C0332185
UMLS CUI [2,2]
C2826667
UMLS CUI [2,3]
C0003280
UMLS CUI [3,1]
C0332185
UMLS CUI [3,2]
C2826667
UMLS CUI [3,3]
C0016018
After
Description

Follow-up Medication- Recording limited to treatment with anti-platelet-agents, anti-coagulant-agents, fibrinolytics and medication given as corrective treatment foradverse events, starting with the day after the last dose of study drug or the day of venography, whichever occurs last, to the end of the follow-up period.

Type de données

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C2347804
UMLS CUI [1,4]
C2963157
UMLS CUI [2,1]
C2347852
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C2347804
UMLS CUI [2,4]
C0003280
UMLS CUI [3,1]
C2347852
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C2347804
UMLS CUI [3,4]
C0016018
UMLS CUI [4,1]
C2347852
UMLS CUI [4,2]
C0687676
UMLS CUI [4,3]
C2347804
UMLS CUI [4,4]
C0392360
UMLS CUI [4,5]
C0877248
Duration Dates: Start
Description

Concomitant Medication Start Date

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C2347852
Duration Dates: End
Description

Concomitant Medication Stop Date

Type de données

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C2347852
Ongoing at the end of the study
Description

Ongoing Concomitant Medication

Type de données

boolean

Alias
UMLS CUI [1]
C2826666
Indication
Description

Concomitant Medication Indication

Type de données

text

Alias
UMLS CUI [1]
C2826696
AE form number
Description

AE form number

Type de données

integer

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0684224
UMLS CUI [1,3]
C0600091
Retour au début de la page

Similar models

Medication Record

1 Formulaires
  1. StudyEvent: ODM
    1. Medication Record
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative data
C1320722 (UMLS CUI-1)
Country No.
Item
Country No.
integer
C0454664 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Centre No.
Item
Centre No.
integer
C1301943 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Clinical Trial Subject Unique Identifier
Item
Subject No.
integer
C2348585 (UMLS CUI [1])
Subject Initials
Item
Subject Initials
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
No Concomitant Medication
Item
None
boolean
C2347852 (UMLS CUI [1,1])
C0549184 (UMLS CUI [1,2])
Item Group
Concomitant Medication Record
C2347852 (UMLS CUI-1)
Drug Name
Item
Drug Name
text
C0013227 (UMLS CUI [1])
Concomitant Agent Total Daily Dose
Item
Total Daily Dose/Units
text
C2826638 (UMLS CUI [1])
Concomitant Medication Route
Item
Route
text
C2826730 (UMLS CUI [1])
Recent prior concomitant medication (Anti-platelet agents, anticoagulants, fibrinolytics)
Item
Prior
boolean
C0332185 (UMLS CUI [1,1])
C2826667 (UMLS CUI [1,2])
C2963157 (UMLS CUI [1,3])
C0332185 (UMLS CUI [2,1])
C2826667 (UMLS CUI [2,2])
C0003280 (UMLS CUI [2,3])
C0332185 (UMLS CUI [3,1])
C2826667 (UMLS CUI [3,2])
C0016018 (UMLS CUI [3,3])
Concomitant medication (anti-platelet agents, anti-coagulants, fibrinolytics or drugs for AEs) taken after study
Item
After
boolean
C2347852 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
C2963157 (UMLS CUI [1,4])
C2347852 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C2347804 (UMLS CUI [2,3])
C0003280 (UMLS CUI [2,4])
C2347852 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C2347804 (UMLS CUI [3,3])
C0016018 (UMLS CUI [3,4])
C2347852 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
C2347804 (UMLS CUI [4,3])
C0392360 (UMLS CUI [4,4])
C0877248 (UMLS CUI [4,5])
Concomitant Medication Start Date
Item
Duration Dates: Start
date
C0808070 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Concomitant Medication Stop Date
Item
Duration Dates: End
date
C0806020 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Ongoing Concomitant Medication
Item
Ongoing at the end of the study
boolean
C2826666 (UMLS CUI [1])
Concomitant Medication Indication
Item
Indication
text
C2826696 (UMLS CUI [1])
AE form number
Item
AE form number
integer
C0877248 (UMLS CUI [1,1])
C0684224 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial